- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04893499
A Study of Chios Mastic Water in Irritable Bowel Syndrome (MASTIQUA)
The Effectiveness of a Natural Aqueous Extract of Chios Mastic in the Management of Irritable Bowel Syndrome: the MASTIQUA Randomized Controlled Clinical Trial
Study Overview
Status
Conditions
Detailed Description
Chios mastic is the resin of the mastic tree (Pistacia Lentiscus var. Chia), produced exclusively in the southern part of the Greek island of Chios. References about its medical use from local populations for the treatment of gastrointestinal disorders or as a cosmetic agent can be found in ancient texts. Nowadays, this versatile resin has been rediscovered, not only as a traditional remedy and aromatic agent, but as a potent phytotherapeutic product with strong anti-inflammatory, anti-microbial and anti-oxidant properties. In 2015, Chios mastic was recognized as a herbal medicinal product by the European Medicines Agency (EMA), with two therapeutic indications: mild dyspeptic disorders and skin inflammation/healing of minor wounds (EMA/HMPC/46758/2015). Over the last years, Chios mastic is widely used in medicinal products, food supplements and cosmetics and has become the object of intense study in the fields of Nutrition and Pharmacotechnology.
Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disease characterized by adverse changes in bowel function (frequency of bowel movements and/or stool composition) and abdominal pain. The clinical presentation of IBS usually includes symptoms of abdominal pain, flatulence, bloating, diarrhea and constipation that often alternate, while postprandial discomfort in the upper abdomen, feeling of fullness, nausea, vomiting and back pain are less commonly reported. IBS affects approximately 7-16% of the general population, and leads to reduced functionality and productivity and a significant deterioration in quality of life due to its various intestinal manifestations. The first-line pharmacological treatments for IBS aim at alleviating symptoms and include antispasmodics or anticonvulsants for abdominal pain, antidiarrheal medication and laxatives for constipation. Dietary modifications, such as the avoidance of foods that aggravate gastrointestinal symptoms and various types of exclusion diets, are also applied as adjunctive therapies for IBS management, but evidence of their effectiveness remains scares and inconclusive.
The use of foods/beverages enriched with Chios mastic could constitute a promising complementary approach for the management of IBS, in combination with current first-line pharmacological treatments. The aim of the present interventional study is to explore the effectiveness of a natural aqueous extract of Chios mastic in the management of IBS.
The study will be a 3-month parallel, randomized (allocation ratio 1:1), controlled, double-blind clinical trial in a sample of 60 adult patients with IBS. Eligible participants will be adult (18-65 years old) otherwise healthy individuals with an IBS diagnosis based on ROME IV criteria under stable medication. Participants will be excluded on the basis of the presence of other chronic gastrointestinal diseases, the presence of other serious comorbidities, or recent significant changes in lifestyle habits. Participants will be randomized to a low-dose mastic group (LDMG), a low-dose control group (LDCC), a high-dose mastic group (HDMG) or a high-dose control group (HDCC). The LDMG will be provided with 600 mL of a sparkling water (mastiqua) containing the natural mastic aqueous extract (0.06%) to be consumed daily (3 bottles of 200 mL each). The HDMG will be provided with 600 mL of a sparkling fruit juice (mastiqua lemon) containing the natural mastic aqueous extract (0.55%) to be consumed daily (3 bottles of 200 mL each). The LDCC and HDCC will receive the same quantity of a placebo sparkling water or fruit juice, respectively. For each type of drink (water and fruit juice), the intervention and placebo drinks will be unlabeled and identical in appearance and organoleptic characteristics, including the characteristic Chios mastic aroma. Randomization will be performed by an investigator with no clinical involvement, while all patients and study team members will be blinded to patient allocation in study groups.
All enrolled patients will continue their standard medical treatment which must remain stable throughout the trial. The study physician will systematically record potential side-effects and will be in charge of terminating the intervention if needed. Participants will be assessed in terms of anthropometric indices (body weight, height, waist circumference, and body composition), lifestyle habits (diet and physical activity habits), the presence and severity of gastrointestinal symptoms, and quality of life both pre- and post-intervention. In addition, blood samples after a 12-hour fast and morning urine samples will be collected to measure biochemical, inflammatory and oxidative stress markers.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Attica
-
Kallithea, Attica, Greece, 17676
- Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 years old
- Body mass index 18.5-35 kg/m2
- IBS diagnosis
Exclusion Criteria:
- Presence of other gastrointestinal disorders, such as gastritis, peptic ulcer, functional dyspepsia, celiac disease and inflammatory bowel disease
- Presence of other serious comorbidities, such as diabetes mellitus, active cancer, cardiovascular disease, pulmonary, kidney, liver, chronic inflammatory, autoimmune or psychiatric diseases
- Recent (within 6 months) surgery or hospitalization
- Habitual excessive alcohol consumption (> 210 or > 140 gr of alcohol per week for men and women, respectively)
- Currently on a weight-loss diet or recent change (within 6 months) in lifestyle habits
- Pregnancy or breast feeding (for women)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-dose mastic group
This arm will consume 600 mL of a sparkling water enriched with Chios mastic per day for a 3-month period.
|
Participants randomized to this intervention arm will be provided with a sparkling water enriched with the natural mastic aqueous extract (0.06%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months.
Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Other Names:
|
Placebo Comparator: Low-dose control group
This arm will consume 600 mL of a standard sparkling water per day for a 3-month period.
|
Participants randomized to this intervention arm will be provided with a standard sparkling water and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months.
Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
|
Experimental: High-dose mastic group
This arm will consume 600 mL of a sparkling fruit juice enriched with Chios mastic per day for a 3-month period.
|
Participants randomized to this intervention arm will be provided with a sparkling fruit juice enriched with the natural mastic aqueous extract (0.55%), a by-product of Chios mastic processing, and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months.
Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
Other Names:
|
Placebo Comparator: High-dose control group
This arm will consume 600 mL of a standard sparkling fruit juice per day for a 3-month period.
|
Participants randomized to this intervention arm will be provided with a standard sparkling fruit juice and will be asked to consume it daily (3 bottles of 200 mL each) for 3 months.
Participants will also be instructed to keep the use of medication and dietary supplements stable and preserve their typical lifestyle habits throughout the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in IBS symptoms severity assessed through the IBS Symptom Severity Scale (IBS-SSS)
Time Frame: 0 (baseline) and 12 weeks
|
The score ranges from 0 to 500, with higher values indicating more severe symptoms.
|
0 (baseline) and 12 weeks
|
Change in quality of life assessed through the IBS Quality of Life questionnaire (IBS-QOL)
Time Frame: 0 (baseline) and 12 weeks
|
Τhe score ranges from 34 to 170 with higher values indicating lower quality of life.
|
0 (baseline) and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in high-sensitivity C-reactive protein
Time Frame: 0 (baseline) and 12 weeks
|
High-sensitivity C-reactive protein (mg/L) will be measured in blood samples by nephelometry.
|
0 (baseline) and 12 weeks
|
Change in high-sensitivity interleukin-6 levels
Time Frame: 0 (baseline) and 12 weeks
|
High-sensitivity interleukin-6 levels (pg/mL) will be measured in blood samples using commercially available ELISA kits.
|
0 (baseline) and 12 weeks
|
Change in malondialdehyde
Time Frame: 0 (baseline) and 12 weeks
|
Malondialdehyde levels (nmol/mL) will be measured in blood samples through HPLC-Fluorescence.
|
0 (baseline) and 12 weeks
|
Change in total serum antioxidant capacity
Time Frame: 0 (baseline) and 12 weeks
|
Total serum antioxidant capacity (μmol/L) will be measured in blood samples using commercially available ELISA kits.
|
0 (baseline) and 12 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Labros Sidossis, PhD, Department of Kinesiology and Health, School of Arts and Sciences, Rutgers University
- Study Chair: Michael Georgoulis, PhD, Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
- Study Chair: Alexandra Karachaliou, MSc, Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Γ-1038/12-3-2021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irritable Bowel Syndrome
-
ProgenaBiomeRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome Characterized by Constipation | Irritable Bowel Syndrome Mixed | Irritable Bowel Syndrome Without Diarrhea | Irritable Bowel | Irritable Bowel Syndrome Aggravated and other conditionsUnited States
-
ClasadoCR2O B.V.RecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome - Constipation | Irritable Bowel Syndrome - Diarrhoea | Irritable Bowel Syndrome - MixedBelgium, Netherlands, United Kingdom
-
Istanbul Medipol University HospitalTepecik Training and Research Hospital; Bozyaka Training and Research Hospital and other collaboratorsRecruitingIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedTurkey
-
Federal Stare Budgetary Scientific Institution,...I.M. Sechenov First Moscow State Medical University; RML INVEST, Torkhovsky...CompletedIrritable Bowel Syndrome | Irritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Constipation | Irritable Bowel Syndrome MixedRussian Federation
-
University of California, Los AngelesCompletedIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome With Mixed Bowel HabitsUnited States
-
University of ViennaCompleted
-
Thomayer University HospitalCharles University, Czech RepublicActive, not recruitingIrritable Bowel Syndrome With Diarrhea | Irritable Bowel Syndrome MixedCzechia
-
Shahid Beheshti University of Medical SciencesCompletedIrritable Bowel DiseaseIran, Islamic Republic of
-
Universidad Autonoma de ChihuahuaNot yet recruitingIrritable Bowel Syndrome | Constipation-predominant Irritable Bowel Syndrome | Diarrhea- Irritable Bowel Syndrome
-
Vasily IsakovRussian Science Foundation; Azbuka vkusa; Federal Research Centre of Nutrition...CompletedIrritable Bowel Syndrome With Constipation | Constipation-predominant Irritable Bowel SyndromeRussian Federation
Clinical Trials on Chios mastic water
-
AHEPA University HospitalSkylitseio General Hospital of ChiosCompletedHypercholesterolemia | HyperlipidemiasGreece
-
Seoul National University HospitalCompletedFunctional DyspepsiaKorea, Republic of
-
Iosif SifakakisCompletedHalitosis | Orthodontic Appliance ComplicationGreece
-
Boston Children's HospitalWithdrawnRegional Anesthesia MorbidityUnited States
-
Essentia Water, LLCHealth Onvector Inc.Completed
-
University of ManitobaCompleted
-
University Hospital, MontpellierCompletedHealthy | Heat ExposureFrance
-
Imam Abdulrahman Bin Faisal UniversityThe Saline Water Conversion Corporation Research Institute at Al-Jubail,...CompletedDiabetes Mellitus | Glucose, High Blood | PatientsSaudi Arabia
-
University of FloridaWithdrawnWeight Loss | Appetitive Behavior | Energy Intake | Water
-
Singapore General HospitalUnknown